Krebs Biochemicals and Industries LimitedQ1 FY27 Results & Financial Update
Krebs Biochemicals and Industries Limited: Q1 FY27 standalone results and company financials – revenue ₹6.98 Cr, PAT ₹-2.48 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Krebs Biochemicals and Industries price & chart
Market price₹57.36
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Krebs Biochemicals and Industries Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Krebs Biochemicals and Industries Limited reported revenue from operations of INR 6.98 crore (698.35 lakh) for the first quarter ended June 30, 2026, alongside other income of INR 0.16 crore (15.65 lakh), bringing total income to INR 7.14 crore.
The company incurred a net loss (PAT) of INR 2.48 crore (248.48 lakh) for Q1 FY27, continuing a prolonged period of bottom-line losses while remaining flat compared to the preceding quarter's loss of INR 2.34 crore.
Operating performance remained heavily constrained by the continued closure of the company's Vizag manufacturing unit, which has been shut down since February 7, 2025, pursuant to orders from the Andhra Pradesh Pollution Control Board.
Total expenses for the quarter stood at INR 9.62 crore, driven by fixed overhead costs including employee benefit expenses of INR 2.78 crore, finance costs of INR 1.88 crore, and depreciation and amortization of INR 1.59 crore.
Despite the plant closure and minimal production operations, the company incurred stock-in-trade purchases of INR 0.51 crore and other operating expenses of INR 2.97 crore.
Basic and diluted earnings per share for the quarter were reported at a negative INR 1.15, reflecting the unannualized loss per share based on a paid-up equity share capital of INR 21.56 crore.
Management announced a significant corporate development during the quarter, with the Board of Directors approving the amalgamation of Krebs Biochemicals & Industries Limited with Ipca Laboratories Limited, subject to necessary statutory and regulatory approvals.
Krebs Biochemicals and Industries Limited reported revenue from operations of INR 6.9835 crore for the first quarter of fiscal year 2027, accompanied by other income of INR 0.1565 crore, bringing total income to INR 7.14 crore.
01 · Business model
What does Krebs Biochemicals and Industries do?
Krebs Biochemicals and Industries Limited manufactures and sells biochemicals, active pharmaceutical ingredients (APIs), and related chemical intermediaries, operating primarily through a standalone entity structure.
The company's primary manufacturing facility is located in Visakhapatnam, Andhra Pradesh, which serves as the core operational base for its production activities.
The economic model relies on large-scale fermentation and chemical synthesis processes to supply specialized biochemical products to domestic and industrial customers.
Commercial operations have faced significant headwinds from regulatory closure orders impacting its primary plant, shifting the business focus toward resolution talks and corporate restructuring.
02 · Historical context
What shaped the business before this quarter
The company's primary manufacturing facility in Visakhapatnam was ordered closed on February 7, 2025, by the Andhra Pradesh Pollution Control Board, halting core production.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹6.98 Cr |
| Total income | ₹7.14 Cr |
| Profit before tax | ₹-2.48 Cr |
| Profit after tax | ₹-2.48 Cr |
| EPS | ₹-1.15 |
Financial interpretation
What the reported numbers mean
Profit after tax represented -35.6% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to -35.6% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹0.16 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue from operations reached INR 6.98 crore for Q1 FY27, reflecting trading or alternate commercial activities while the main manufacturing plant remained shut.
Other income added INR 0.16 crore to the top-line during the quarter, dropping significantly from INR 2.00 crore reported in the preceding quarter.
The company recorded revenue from operations of INR 6.9835 crore for Q1 FY27 alongside other income of INR 0.1565 crore.
What drove margins
Finance costs of INR 1.88 crore and depreciation of INR 1.59 crore weighed heavily on the net outcome given the limited operational revenue of INR 6.98 crore.
Employee benefit expenses stood at INR 2.78 crore, while other expenses accounted for INR 2.97 crore, representing the fixed operational cost base during the plant shutdown.
Despite the continued suspension of manufacturing operations at the Vizag plant, the company incurred ongoing fixed commitments including employee benefits of INR 2.7792 crore and finance costs of INR 1.8805 crore.
Depreciation and amortisation expense stood at INR 1.5878 crore while other expenses accounted for INR 2.9661 crore during the quarter.
05 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company operates in one primary business segment only, hence separate segment results have not been disclosed.
06 · Strategy & new businesses
How the company is trying to change its growth mix
The Board of Directors approved the amalgamation of Krebs Biochemicals & Industries Limited with Ipca Laboratories Limited on June 26, 2026, with an appointed date of April 1, 2026, pending statutory consents and approvals.
07 · Reported developments
What changed operationally
Statutory auditors issued an unmodified review report on the standalone financial results for the quarter ended June 30, 2026.
Statutory auditors issued an unmodified review report on the unaudited standalone financial results for Q1 FY27.
08 · Pressure points & risks
What is not going smoothly
The Visakhapatnam manufacturing unit remained non-operational throughout the quarter due to the Andhra Pradesh Pollution Control Board closure order.
The company reported a negative net worth including retained earnings of INR 16,275.47 lakh (INR 162.75 crore) as of June 30, 2026.
09 · Beyond the numbers
What changed beyond the numbers
Reported update
Regulatory dialogue
The company has taken various steps and remains in constant dialogue with the Andhra Pradesh Pollution Control Board for the revocation of the closure order.
10 · Previous-quarter changes
What changed since the previous quarter
Net loss for Q1 FY27 stood at INR 2.48 crore compared to a net loss of INR 2.34 crore in Q4 FY26.
11 · Key Q&A
The quarter, answered directly
What does Krebs Biochemicals and Industries do?
Krebs Biochemicals and Industries Limited manufactures and sells biochemicals, active pharmaceutical ingredients (APIs), and related chemical intermediaries, operating primarily through a standalone entity structure.
What is the clearest takeaway from Q1 FY27?
Krebs Biochemicals and Industries Limited reported revenue from operations of INR 6.98 crore (698.35 lakh) for the first quarter ended June 30, 2026, alongside other income of INR 0.16 crore (15.65 lakh), bringing total income to INR 7.14 crore.
What drove revenue or demand?
Revenue from operations reached INR 6.98 crore for Q1 FY27, reflecting trading or alternate commercial activities while the main manufacturing plant remained shut.
What mattered most for margins or profitability?
Finance costs of INR 1.88 crore and depreciation of INR 1.59 crore weighed heavily on the net outcome given the limited operational revenue of INR 6.98 crore.
What changed operationally beyond the headline numbers?
The Board of Directors approved the amalgamation of Krebs Biochemicals & Industries Limited with Ipca Laboratories Limited on June 26, 2026, with an appointed date of April 1, 2026, pending statutory consents and approvals.
What are the main pressure points disclosed for the quarter?
The Visakhapatnam manufacturing unit remained non-operational throughout the quarter due to the Andhra Pradesh Pollution Control Board closure order.
12 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.